CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025)
CollPlant Biotechnologies (CLGN) reported FCF Margin of 4866.67% for Q4 2025, down 279045.0% on a YoY basis from N/an in Q4 2024, and down 30.3% quarter-over-quarter from 3735.06% in Q3 2025.
CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies has reported FCF Margin for 8 years, with the latest figure at 4866.67% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 279045.0% year-over-year to 4866.67%; the trailing twelve-month figure through Dec 2025 stood at 396.08% (up 224664.0% YoY), and the FY2025 full-year result was 396.08%, up 224664.0% from the prior year.
- FCF Margin for Q4 2025 stood at 4866.67%, down from 3735.06% in the prior quarter.
- The five-year high for FCF Margin was 77.52% in Q1 2021, with the low at 82700.0% in Q3 2024.
- Historically, FCF Margin has averaged 6988.51% across 5 years, with a median of 1496.39% in 2024.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 8270002 bps — and 2025, when it jumped 7896494 bps.
- CollPlant Biotechnologies' FCF Margin stood at 320.0% in 2021, then slumped by 6594 bps to 21420.69% in 2022, then surged by 97 bps to 707.69% in 2023, then plunged by 193 bps to 2076.22% in 2024, then tumbled by 134 bps to 4866.67% in 2025.
- The last three FCF Margin figures came in at 4866.67% (Q4 2025), 3735.06% (Q3 2025), and 1361.45% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,866.67% |
| Sep 30, 2025 | -3,735.06% |
| Jun 30, 2025 | -1,361.45% |
| Mar 31, 2025 | -56.35% |
| Dec 31, 2024 | -2,076.22% |
| Sep 30, 2024 | -82,700.00% |
| Jun 30, 2024 | -1,496.39% |
| Mar 31, 2024 | -3,235.71% |
| Dec 31, 2023 | -707.69% |
| Sep 30, 2023 | 0.02% |
| Jun 30, 2023 | -33.45% |
| Mar 31, 2023 | -763.28% |
| Dec 31, 2022 | -21,420.69% |
| Sep 30, 2022 | -2,638.53% |
| Jun 30, 2022 | -5,413.64% |
| Dec 31, 2021 | -320.00% |
| Sep 30, 2021 | -1,580.00% |
| Jun 30, 2021 | -454.12% |
| Mar 31, 2021 | 77.52% |
| Dec 31, 2020 | -65.47% |